Understanding this distinction helps prioritize safety in the medication-use process. A medication error is a preventable mistake that can occur at prescribing, dispensing, or administering a drug. An adverse drug event (ADE) is harm caused by the drug itself. They are not the same because the error focuses on a mistake in the process that could be avoided, while the ADE focuses on the injury from the drug, which can happen even without an error. Not all ADEs come from errors—some are predictable side effects or reactions despite correct use—and not every medication error results in harm. This relationship means preventing medication errors can reduce some ADEs, but ADEs can still occur even when care is appropriate.

Safe IV push technique hinges on aseptic practice, maintaining line patency with saline flushes, delivering the medication at the prescribed rate, and watching for reactions. Using aseptic technique prevents introducing infection into the bloodstream during a needle or catheter–based drug delivery. Flushing with saline before and after each med ensures the line remains patent, clears any residual medication from previous doses, and helps prevent drug–drug or line–related interactions. Administering the dose slowly per the order controls the rate to reduce the risk of adverse reactions, extravasation, or venous irritation. Monitoring for adverse reactions during and after the injection allows immediate action if issues arise, such as allergic responses or local/systemic effects. Choosing approaches that skip sterile technique, omit flushing, administer too quickly, or ignore comprehensive monitoring would increase infection risk, line occlusion or incompatibility problems, greater potential for harm from rapid administration, and delayed recognition of adverse effects.

Iodinated contrast media can cause damage to the kidneys. The kidneys are responsible for filtering and excreting the contrast agent, so they are at risk for contrast-induced nephropathy. After administration, kidney injury may show up as a rise in creatinine within about 24 to 72 hours. Those at higher risk—such as people with preexisting kidney disease, dehydration, diabetes, or older adults—are more susceptible. The mechanism involves a combination of reduced renal blood flow due to vasoconstriction in the kidneys and direct tubular toxicity from the contrast material. Preventive steps include ensuring adequate hydration, using the lowest effective dose, and opting for contrast types with lower nephrotoxic potential when possible. While reactions to contrast can affect other systems in rare cases, the organ most commonly damaged by iodinated contrast is the kidneys.

Monitoring for digoxin toxicity involves a comprehensive safety check that combines heart rate assessment, kidney function, electrolyte balance, symptom surveillance, and drug level if ordered. The pulse check before administration is essential because digoxin can slow AV conduction and cause dangerous bradycardia; if the pulse is too low, the dose should be held. Because digoxin is cleared by the kidneys, evaluating renal function is crucial—impaired kidneys raise the chance of drug buildup and toxicity. Potassium levels matter too: hypokalemia increases digoxin’s effects and risk of toxicity, so potassium is monitored and corrected as needed. Be vigilant for the characteristic signs across systems—GI symptoms like nausea, vomiting, and loss of appetite; vision changes such as blurred vision or yellow-green halos; and cardiac issues including various arrhythmias. If a digoxin level is ordered, obtaining it helps interpret whether the patient is within the therapeutic range and guides management, especially when toxicity is suspected. This broad monitoring approach is necessary because focusing on only one symptom or measurement (like blood pressure or headaches) can miss the key early warning signs of toxicity and puts the patient at risk.